PeptiDream Inc.
4587・Prime Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 6 members (2 executive directors and 4 Audit and Supervisory Committee members), with 4 independent outside directors constituting a majority. Three voluntary advisory committees have been established: the Nomination and Compensation Committee, the Sustainability and Governance Committee, and the Compliance and Risk Management Committee. A full-time Audit and Supervisory Committee member serves as chairman of the Board of Directors.
Risk Management
The company has established the "Risk Management Regulations" and conducts risk management through a PDCA cycle centered on the Compliance and Risk Management Committee (held quarterly). In 2025, it was discovered that a former Representative Director, Executive Vice President and COO had improperly ordered and removed reagents (up to 752 items, equivalent to approximately ¥54 million). Recurrence prevention measures were formulated and implemented, including the introduction of an IT system, a review of the organizational structure, enhanced periodic monitoring, and the establishment of an Executive Leadership Team. The impact on the financial statements has been confirmed to be minor.
Shareholder Returns
No dividends for FY2025 (ending December 2025) and FY2026 (ending December 2026) (annual dividend of ¥0.00). Share buybacks of ¥997,795 thousand were conducted in the current quarter. The company continues its policy of prioritizing internal retention of funds for research and development.
Dividend Policy
The annual dividend for FY2025 (ending December 2025) is ¥0.00 (no dividend). The forecast for FY2026 (ending December 2026) is also an annual dividend of ¥0.00 (no dividend). The policy is to consider dividend payments when stable earnings can be secured in the future and sufficient profit to cover research and development funding needs can be ensured, taking into comprehensive account the necessity of building up internal reserves and other factors.
ESG
Identified 11 materiality issues, approved by the Board of Directors. On climate change response, established SBTi-certified GHG reduction targets (100% reduction in Scope 1+2 by 2030 versus 2023, and 20% reduction in Scope 3) and conducted third-party verification. In human capital, disclosed diversity metrics for core personnel (proportion of PhD holders, foreign nationals, young employees, and women) and engagement scores as 2030 targets. Established a framework in which the Sustainability Governance Committee reports to the Board of Directors on a quarterly basis.
Last updated: March 18, 2026